Brief: Biohaven Enters Strategic Licensing Agreement With Ono Pharma
08/10/2026 11:45
BRIEF-Biohaven Enters Strategic Licensing Agreement With Ono Pharma Oct 8 (Reuters) - ONO PHARMACEUTICAL CO., LTD. 4528.T:
BIOHAVEN ENTERS STRATEGIC LICENSING AGREEMENT WITH ONO PHARMA FOR EXTRACELLULAR IGG DEGRADERS IN JAPAN AND SELECT ASIAN REGIONS, LEAD CANDIDATE BHV-1300 IN PHASE 3 FOR GRAVES' DISEASE
BIOHAVEN - TO RECEIVE UP TO $100 MILLION PAYMENTS AND 20% ROYALTIES FROM ONO
BIOHAVEN - ONO OBTAINS EXCLUSIVE LICENSE FOR BIOHAVEN'S IGG DEGRADERS IN JAPAN, SOUTH KOREA, TAIWAN, ASEAN
Source text: ID:nPn2Q48Rba
Further company coverage: 4528.T
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ONO PHARMACEUTICAL
See all newsBrief: Biohaven Enters Strategic Licensing Agreement With Ono Pharma
Ono Pharma Announces An Exclusive License Agreement With Biohaven To Develop And Commercialize Igg Degraders In Japan, South Korea, Taiwan, And Asean
Bristol Myers sues Amgen over proposed Opdivo biosimilar (updated)
Bristol Myers sues Amgen over proposed Opdivo biosimilar
Brief: UK's MHRA Says Vimseltinib Approved For Use In Adults To Treat Tenosynovial Giant Cell Tumours